Disease / condition

Papillomavirus Infections clinical trials

Free access to 28 studies·10+ countries·Updated daily8 recruiting
28
Total trials
10+
Countries
10+
Sponsors
8
Recruiting
By phase
Phase 313
N/A10
Phase 12
Phase 22
Phase 41
By status
Completed15
Not yet recruit...8
Terminated3
Unknown2
Top countries
China5
United States of America5
Canada,United States of America1
Colombia,Mexico,Poland,South Africa,Taiwan,United States of America1
Greece1
Top sponsors
Merck Sharp & Dohm...9
University of Wash...5
Merck Sharp & Dohm...5
Takeda2
Inovio Pharmaceuti...1
Recent trials
Latest clinical trials for Papillomavirus Infections
NCT06399341Completed
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
Elpen Pharmaceutical Co. Inc.Greece
NCT05450705·Phase 3Not yet recr...
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
Merck Sharp & Dohme LLCChina
NCT05285826·Phase 3Not yet recr...
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
Merck Sharp & Dohme LLCChina
NCT04772534·Phase 3Not yet recr...
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
Merck Sharp & Dohme Corp.Japan
NCT04708041·Phase 3Not yet recr...
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
Merck Sharp & Dohme Corp.Colombia,Mexico,Poland,South Africa,Taiwan,United States of America
NCT04199689·Phase 3Not yet recr...
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
Merck Sharp & Dohme Corp.Belgium,Brazil,Colombia,Czech,France,Germany,Israel,Italy,Japan,South Korea,Mexico,Peru,Spain,Taiwan
NCT03998254·Phase 3Not yet recr...
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
Merck Sharp & Dohme Corp.China
NCT03929172·Phase 1Completed
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
2A Pharma ABUnited Kingdom
NCT03903562·Phase 3Not yet recr...
Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
Merck Sharp & Dohme Corp.China
NCT03675256·Phase 4Not yet recr...
The KEN SHE Study on HPV-vaccine Efficacy
University of WashingtonKenya
NCT03548740
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
Peking Union Medical College H...China
NCT02845739Completed
PApillomavirus in REnal Transplant Patient
Centre Hospitalier Universitai...
NCT01355003Terminated
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
Merck Sharp & Dohme LLC
NCT01295242Completed
Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM)
University of WashingtonUnited States of America
NCT01254643·Phase 3Completed
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
Merck Sharp & Dohme LLC
NCT01245764·Phase 3Completed
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
NCT01101828Completed
Self-collected Swabs for HPV Testing in 18-24 Year Old Women
University of WashingtonUnited States of America
NCT01073293·Phase 3Completed
A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)
Merck Sharp & Dohme LLC
NCT00743392Completed
HPV Infections in Older Women
University of WashingtonUnited States of America
NCT00685412·Phase 1Completed
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
Inovio PharmaceuticalsPuerto Rico,United States of America
About this record

Access comprehensive clinical trial information for Papillomavirus Infections through Pure Global AI's free database. This collection includes 28 clinical trials across multiple phases including Phase 3, N/A, Phase 1. Currently, 8 trials are actively recruiting participants.

Research for Papillomavirus Infections is being conducted in China, United States of America, Canada,United States of America and 7+ other countries. Leading sponsors include Merck Sharp & Dohme LLC and University of Washington. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.

Pure Global AI provides free access to 28 clinical trials studying Papillomavirus Infections, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.

The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.

Top research sponsors include Merck Sharp & Dohme LLC, University of Washington, Merck Sharp & Dohme Corp., among others.